{
    "nct_id": "NCT04386993",
    "official_title": "De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer (DeCRESCEndo)",
    "inclusion_criteria": "* Histologically or cytologically confirmed stage IIIA-IVA endometrial cancer, or any stage I-IVA where any proportion of the tumor is uterine serous, clear cell, de-differentiated, or carcinosarcoma histology.\n* Must have already undergone radical hysterectomy. Hysterectomy may have occurred no more than one year prior to enrollment.\n* At least 18 years of age.\n* ECOG performance status ≤ 2\n* Minimal bone marrow and organ function as defined below:\n\n  * Leukocytes ≥ 1,000 cumm\n  * Absolute neutrophil count ≥ 500 cumm\n  * Platelets ≥ 50,000 cumm\n  * Hemoglobin ≥ 7g/dL\n* Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior radiation to the pelvis.\n* Currently receiving any investigational agents.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, inflammatory bowel disease, or irritable bowel disease.\n* Patients with HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.",
    "miscellaneous_criteria": ""
}